• J Bauzá-Martinez, F Aletti, B B Pinto, V Ribas, M A Odena, R Díaz, E Romay, R Ferrer, E B Kistler, G Tedeschi, G W Schmid-Schönbein, A Herpain, K Bendjelid, and E de Oliveira.
• Proteomics Platform, Barcelona Science Park, Barcelona, Spain.
• Br J Anaesth. 2018 Nov 1; 121 (5): 1065-1074.

BackgroundUncontrolled proteolysis contributes to cell injury and organ dysfunction in animal models of circulatory shock. We investigated in humans the relationship between septic shock, proteolysis, and outcome.MethodsIntensive care patients with septic shock (n=29) or sepsis (n=6) and non-hospitalised subjects (n=9) were recruited as part of the prospective observational trial 'ShockOmics' (ClinicalTrials.gov Identifier NCT02141607). A mass spectrometry-based approach was used to analyse the plasma peptidomes and the origin of circulating peptides from proteolysis in the enrolled subjects.ResultsEvidence of systemic proteolysis was indicated by a larger number of circulating peptides in septic shock patients, compared with septic patients and non-hospitalised healthy subjects. The peptide count and abundance in the septic shock patients were greater in patients who died (n=6) than in survivors (n=23), suggesting an association between magnitude of proteolysis and outcome. In silico analysis of the peptide sequences and of the sites of cleavage on the proteins of origin indicated a predominant role for serine proteases, such as chymotrypsin, and matrix metalloproteases in causing the observed proteolytic degradation.ConclusionsSystemic proteolysis is a novel fundamental pathological mechanism in septic shock. Plasma peptidomics is proposed as a new tool to monitor clinical trajectory in septic shock patients.Clinical Trial RegistrationNCT02141607.Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

32 keywords...

hide…